148 related articles for article (PubMed ID: 22027747)
1. Expression of NLK and its potential effect in ovarian cancer chemotherapy.
Zhang Y; Peng C; Wu G; Wang Y; Liu R; Yang S; He S; He F; Yuan Q; Huang Y; Shen A; Cheng C
Int J Gynecol Cancer; 2011 Nov; 21(8):1380-7. PubMed ID: 22027747
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of nemo-like kinase is an independent prognostic factor in colorectal cancer.
Zhang W; He J; Du Y; Gao XH; Liu Y; Liu QZ; Chang WJ; Cao GW; Fu CG
World J Gastroenterol; 2015 Aug; 21(29):8836-47. PubMed ID: 26269673
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of Nemo-like kinase expression in patients with hepatocellular carcinoma.
Chen HW; Qiao HY; Li HC; Li ZF; Zhang HJ; Pei L; Liu HW; Jin L; Wang D; Li JL
Tumour Biol; 2015 Nov; 36(11):8447-53. PubMed ID: 26022162
[TBL] [Abstract][Full Text] [Related]
4. PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin chemotherapy by promoting apoptosis.
Li Q; Gao JF; Qi BL
J BUON; 2017; 22(3):746-756. PubMed ID: 28730785
[TBL] [Abstract][Full Text] [Related]
5. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
Bar JK; Harłozińska A; Popiela A; Noga L
Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
[TBL] [Abstract][Full Text] [Related]
6. NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer.
Han Y; Kuang Y; Xue X; Guo X; Li P; Wang X; Guo X; Yuan B; Zhi Q; Zhao H
Biomed Pharmacother; 2014 Jun; 68(5):497-505. PubMed ID: 24972723
[TBL] [Abstract][Full Text] [Related]
7. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway.
Lv L; Wan C; Chen B; Li M; Liu Y; Ni T; Yang Y; Liu Y; Cong X; Mao G; Xue Q
J Cell Biochem; 2014 Jan; 115(1):81-92. PubMed ID: 23904219
[TBL] [Abstract][Full Text] [Related]
8. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin.
Suwei D; Liang Z; Zhimin L; Ruilei L; Yingying Z; Zhen L; Chunlei G; Zhangchao L; Yuanbo X; Jinyan Y; Gaofeng L; Xin S
J Hematol Oncol; 2015 Oct; 8():120. PubMed ID: 26503334
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer.
Li M; Zhang S; Wang Z; Zhang B; Wu X; Weng H; Ding Q; Tan Z; Zhang N; Mu J; Yang J; Shu Y; Bao R; Ding Q; Wu W; Cao Y; Liu Y
Tumour Biol; 2013 Dec; 34(6):3995-4000. PubMed ID: 23857283
[TBL] [Abstract][Full Text] [Related]
10. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
11. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells.
Chen W; Huang L; Hao C; Zeng W; Luo X; Li X; Zhou L; Jiang S; Chen Z; He Y
Tumour Biol; 2016 Jul; 37(7):9289-99. PubMed ID: 26779627
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
14. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
[TBL] [Abstract][Full Text] [Related]
15. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
[TBL] [Abstract][Full Text] [Related]
16. [Effect and mechanism of endoplasmic reticulum stress on cisplatin resistance in ovarian carcinoma].
Tian J; Hu X; Qu Q
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):324-8. PubMed ID: 25030585
[TBL] [Abstract][Full Text] [Related]
17. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
Ma Y; Cao H; Lou S; Shao X; Lv W; Qi X; Liu Y; Ying M; He Q; Yang X
J Mol Med (Berl); 2015 Apr; 93(4):427-38. PubMed ID: 25411027
[TBL] [Abstract][Full Text] [Related]
18. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.
Surowiak P; Materna V; Kaplenko I; Spaczyński M; Dietel M; Lage H; Zabel M
Virchows Arch; 2005 Sep; 447(3):626-33. PubMed ID: 15968547
[TBL] [Abstract][Full Text] [Related]
19. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
20. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy.
Cantuaria G; Fagotti A; Ferrandina G; Magalhaes A; Nadji M; Angioli R; Penalver M; Mancuso S; Scambia G
Cancer; 2001 Sep; 92(5):1144-50. PubMed ID: 11571727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
